Trials / Not Yet Recruiting
Not Yet RecruitingNCT06745193
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy and safety of a combination treatment of chidamide, camrelizumab, and apatinib in patients with advanced esophageal cancer. This open-label, phase II clinical trial will involve randomly assigning participants to receive either the combination of these drugs or a standard treatment. The primary endpoints is ORR and the second endpoints include progression-free survival and overall survival, while safety will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chidamide+Camrelizumab+Apatinib | chidamide+Camrelizumab+Apatinib |
| DRUG | Irinotecan or Docetaxel or Paclitaxel | Irinotecan Docetaxel Paclitaxel |
Timeline
- Start date
- 2025-02-01
- Primary completion
- 2027-02-01
- Completion
- 2028-02-01
- First posted
- 2024-12-20
- Last updated
- 2024-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06745193. Inclusion in this directory is not an endorsement.